Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial
Conditions
Interventions
OKT3
Locations
1
Israel
Hadassah University Hospital, Liver Unit
Jerusalem, Israel
Start Date
September 1, 2010
Primary Completion Date
December 1, 2010
Completion Date
April 1, 2011
Last Updated
June 23, 2011
NCT02815891
NCT03587831
NCT06216041
NCT03997422
NCT05979779
NCT05479721
Lead Sponsor
Hadassah Medical Organization
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions